---
layout: default
title: Avanafil
parent: 僅模型預測 (L5)
nav_order: 49
evidence_level: L5
indication_count: 0
---

# Avanafil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Avanafil: Drug Repurposing Evaluation — Incomplete Evidence Pack

## One-Sentence Summary

Avanafil (DrugBank: DB06237) is a drug currently not registered in Taiwan, and this Evidence Pack contains **no TxGNN-predicted indications** along with multiple critical data gaps. A formal drug repurposing evaluation cannot be completed at this stage; the recommended action is **Hold** pending remediation of missing data items.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not documented in this Evidence Pack |
| Predicted New Indication | None available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction stage not reached |
| Taiwan Market Status | Not marketed（未上市） |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Evaluation Can Be Completed

The TxGNN pipeline returned **zero predicted indications** for Avanafil in this Evidence Pack. Two blocking data gaps are directly responsible:

**1. Missing mechanism of action (DG002 — High severity)**
Mechanism of action data is absent from the evidence pack. MOA is a core input for TxGNN's knowledge-graph embedding. Without it, drug–disease edge weights cannot be computed, and the model may fail to surface candidate indications.

**2. Missing TFDA package insert warnings and contraindications (DG001 — Blocking severity)**
Taiwan TFDA label data is required to complete the S1 safety pre-screening layer. This gap is classified as Blocking, meaning downstream evaluation steps are gated on its resolution.

Because `predicted_indications` is empty, the following standard sections cannot be generated and are therefore omitted per reporting rules: *Clinical Trial Evidence*, *Literature Evidence*, and *Taiwan Market Information*.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete — no TxGNN-predicted indications are present, and the two most critical data items (MOA and TFDA package insert) are missing. No meaningful repurposing signal can be evaluated or communicated until these gaps are closed.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Download and parse the TFDA package insert PDF for Avanafil to extract approved indications, warnings, and contraindications; this unblocks the S1 safety screening gate
- **[DG002 — High]** Query DrugBank API (`/drugs/DB06237`) to retrieve mechanism of action; this restores full knowledge-graph embedding coverage
- Re-run the TxGNN evidence pipeline with the completed drug profile to generate ranked predicted indications
- Verify DDI data via an alternative source (e.g., DrugBank interaction endpoint or clinical pharmacology database), as the current DDI query returned `not_found`
- Once predicted indications are available, re-initiate this report with a populated Evidence Pack (v5+)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

